ArticleFrontiers in neurology2025
Prognostic factors in aneurysmal subarachnoid hemorrhage with poor initial clinical grade.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Subarachnoid hemorrhage: epidemiology, risk factors, pathogenesis, and clinical therapies.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Aneurysmal subarachnoid hemorrhage (aSAH) is a rare cause of stroke that poses significant morbidity and mortality, as it affects patients around the age of 50 years. While advances in early aneurysm intervention have reduced mortality rates, many patients still experience poor outcomes due to early brain injury (EBI) and delayed cerebral ischemia (DCI). This study aims to explore the characteristics of patients with poor neurological outcomes among patients with poor neurological status at admission, using comprehensive clinical and neuroimaging data. Methods: We analyzed 377 aSAH patients (WFNS 4-5) admitted between 2013 and 2020, focusing on demographics, clinical assessments, imaging, treatments, and outcomes at discharge and 3 months later. Results: Among the cohort, which predominantly consisted of females, the mortality rate was 49%. Our findings indicate that older patients had poorer functional outcomes; notably, 59% of patients aged 75 and older had limitations on therapeutic efforts, leading to a 100% mortality rate in that subgroup. There was no difference in outcomes between endovascular and surgical treatments. However, patients undergoing multimodal monitoring had better functional outcomes at discharge. Angiographic vasospasm was found in 31% of patients and was linked to poorer outcomes at discharge ( Conclusion: The prognosis of patients with aSAH and poor neurological status on admission is generally poor. Multimodal monitoring and tailored treatment appear to be beneficial in achieving favorable results in these patients. Despite the initial severity, up to 20% of patients achieve a good functional result on discharge and up to 35% do so at 3 months. These should be considered in the initial prognostic assessment with the families of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.